Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, and Chicago's major cancer centres including Robert H. Lurie Comprehensive Cancer Center at Northwestern and University of Chicago Medicine treat hundreds of myeloma patients annually who require Lenalidomide-based therapy. Lenalid 25mg — the Indian generic of Revlimid — now makes this life-extending treatment accessible at a dramatically reduced cost.
Lenalid contains Lenalidomide 25mg, an immunomodulatory drug (IMiD) and anti-angiogenic agent with multiple mechanisms of action against myeloma. It stimulates T-cells and natural killer cells to attack myeloma cells, inhibits tumour necrosis factor-alpha, and blocks new blood vessel formation that tumours require to grow. It is used as maintenance therapy after stem cell transplant — where it has been shown to significantly extend progression-free survival — and in combination with dexamethasone for relapsed or refractory disease.
Brand-name Revlimid in Chicago costs over $20,000 per month — one of the most expensive cancer medicines in the USA. With patent expiry, Indian generic Lenalidomide 25mg from WHO-GMP certified manufacturers now provides the same efficacy at savings of thousands of dollars per month. For Chicago myeloma patients who are self-funding, internationally insured, or between insurance coverage, Lenalid offers a critical affordable alternative.
Unnati Pharmax supplies Lenalid 25mg to oncology pharmacies, myeloma clinics, and patients in Chicago and across the USA. Contact medshopy.com or WhatsApp +91 82650 41513 for pricing.
